China Medical System Holdings Limited (2M7C.F)

Compare

0.9400

0.0000

(0.00%)

At close: April 4 at 5:15:01 PM GMT+2

China Medical System （00867） Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum

SHENZHEN, CHINA, March 21, 2025 (GLOBE NEWSWIRE) -- On March 17, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. Profit for the year was RMB1,613 million, and normalized profit for the year that exclu

GlobeNewswire 14 days ago

CHSYF
China Medical System （867.HK） is Included in the S&P Global Sustainability Yearbook 2025

SHENZHEN, CHINA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited (“CMS” or the “Group”) has been included in the S&P Global Sustainability Yearbook 2025 (the “Yearbook 2025”). This marks the Group’s first inclusion in the global edition of S&P Global Sustainability Yearbook (the “Yearbook”), following the S&P Global Sustainability Yearbook (China Edition) i

GlobeNewswire last month

CHSYF
3 Prominent Dividend Stocks To Consider For Your Portfolio

Amidst a backdrop of global market volatility driven by tariff uncertainties and mixed economic indicators, investors are increasingly seeking stable income sources to navigate these turbulent times. Dividend stocks often provide a reliable stream of income and can be an attractive option for those looking to balance their portfolios with consistent returns, especially when market conditions are unpredictable.

Simply Wall St. last month

PIN-F.BK

PIN-R.BK

PIN.BK
China Medical System enters collaboration agreement with Mabgeek Biotechnology

China Medical System (CHSYF) entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology and its subsidiary for Class 1 innovative drug anti-IL-4Ralpha humanized monoclonal antibody injection MG-K10. The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; Mabgeek Biotechn

TipRanks 2 months ago

CHSYF
China Medical System（00867）Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10

SHENZHEN, CHINA, Jan. 24, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The

GlobeNewswire 2 months ago

CHSYF
Top Dividend Stocks For Reliable Income In January 2025

As global markets navigate the complexities of a resilient U.S. labor market and persistent inflation concerns, investors are witnessing choppy conditions with significant fluctuations in major indices like the Nasdaq Composite and Russell 2000. Amidst these uncertainties, dividend stocks can offer a reliable income stream, providing stability through regular payouts even when broader market volatility is at play.

Simply Wall St. 2 months ago

BKAHF

BKAYF

BKAYY
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatme

GlobeNewswire 2 months ago

CHSYF
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China

On Wednesday, Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zunveyl (benzgalantamine) in Asia (excluding Japan), Australia and New Zealand. Zunveyl is a next-generation acetylcholinesterase inhibitor approved in the U.S. for mild-to-moderate Alzheimer's disease. The deal value is $44 million, including $6 million in total upfront payments split into tranches and

Benzinga 2 months ago

CHSYF
China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China

SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicat

GlobeNewswire 3 months ago

CHSYF
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia

SHENZHEN, CHINA, Dec. 02, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of clas

GlobeNewswire 3 months ago

CHSYF
Top Dividend Stocks To Enhance Your Portfolio

As global markets experience broad-based gains with U.S. indexes approaching record highs and economic indicators like initial jobless claims reaching new lows, investors are closely monitoring the Federal Reserve's upcoming decisions on interest rates. In this dynamic environment, dividend stocks stand out as a compelling option for enhancing portfolios, offering potential income stability amid market fluctuations and geopolitical uncertainties.

Simply Wall St. 4 months ago

CHSYF
China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

SHENZHEN, CHINA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital.

GlobeNewswire 5 months ago

CHSYF
3 Dividend Stocks On SEHK Yielding Up To 6.1%

As Hong Kong's Hang Seng Index experiences a significant rally, buoyed by China's recent stimulus measures, investors are increasingly looking at dividend stocks as a reliable source of income amidst the market's volatility. In this context, selecting stocks with strong fundamentals and consistent dividend payouts can be particularly appealing for those seeking stability and potential returns in an evolving economic landscape.

Simply Wall St. 5 months ago

0883.HK

80883.HK

CHSYF
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

SHENZHEN, CHINA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cream in China, followi

GlobeNewswire 6 months ago

CHSYF
Top SEHK Dividend Stocks Including Lion Rock Group

Amid a backdrop of global economic uncertainty and fluctuating market conditions, the Hong Kong market has shown resilience, with investors keenly eyeing stable dividend-paying stocks. In this article, we will explore three top dividend stocks listed on the SEHK, including Lion Rock Group, highlighting their potential to provide consistent returns in these volatile times.

Simply Wall St. 6 months ago

CHSYF

1127.HK

TGRNF
3 SEHK Stocks That May Be Undervalued In September 2024

As global markets experience a mixed performance, the Hong Kong market has shown resilience with the Hang Seng Index gaining 2.14% recently. Amidst this environment, identifying undervalued stocks can be an effective strategy for investors looking to capitalize on potential growth opportunities.

Simply Wall St. 6 months ago

1858.HK

3316.HK

CHSYF
3 SEHK Dividend Stocks Yielding Over 6% For Your Portfolio

The Hong Kong market has shown resilience amid global economic uncertainties, with the Hang Seng Index recently posting a 1.99% gain. As investors navigate these fluctuating conditions, dividend stocks yielding over 6% can offer a reliable income stream and potential portfolio stability.

Simply Wall St. 7 months ago

3988.HK

CHBJF

CHCJY
SEHK Value Stocks Estimated To Be Undervalued In August 2024

As global markets continue to navigate economic uncertainties, the Hong Kong stock market has shown resilience with the Hang Seng Index gaining 1.99% recently. In this environment, identifying undervalued stocks can offer potential opportunities for investors looking to capitalize on market inefficiencies. In this article, we will explore three stocks listed on the SEHK that are estimated to be undervalued as of August 2024. These selections are based on their strong fundamentals and...

Simply Wall St. 7 months ago

ESRCF

CHSYF

2268.HK
China Medical System （00867） Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023

CMS enters the "New Product Era" driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%.SHENZHEN, CHINA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover

GlobeNewswire 7 months ago

CHSYF
Top Dividend Stocks On SEHK To Consider In August 2024

As global markets react to economic data and shifts in investor sentiment, the Hong Kong market has shown resilience amid broader uncertainties. With the Hang Seng Index experiencing modest declines, dividend stocks on the SEHK remain a compelling option for investors seeking stable returns in volatile times. In this environment, selecting dividend stocks with strong fundamentals and consistent payout histories can provide a reliable income stream and mitigate some of the risks associated...

Simply Wall St. 7 months ago

SHTDF

SHTDY

CHSYF

Performance Overview

Return	2M7C.F	HANG SENG INDEX (^HSI)
YTD	+3.87%	+13.91%
1-Year	+55.82%	+36.62%
3-Year	+174.61%	+1.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

China Medical System Holdings Limited (2M7C.F)

China Medical System （00867） Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum

China Medical System （867.HK） is Included in the S&P Global Sustainability Yearbook 2025

3 Prominent Dividend Stocks To Consider For Your Portfolio

China Medical System enters collaboration agreement with Mabgeek Biotechnology

China Medical System（00867）Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10

Top Dividend Stocks For Reliable Income In January 2025

China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type

Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China

China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia

Top Dividend Stocks To Enhance Your Portfolio

China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

3 Dividend Stocks On SEHK Yielding Up To 6.1%

China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Top SEHK Dividend Stocks Including Lion Rock Group

3 SEHK Stocks That May Be Undervalued In September 2024

3 SEHK Dividend Stocks Yielding Over 6% For Your Portfolio

SEHK Value Stocks Estimated To Be Undervalued In August 2024

China Medical System （00867） Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023

Top Dividend Stocks On SEHK To Consider In August 2024

Performance Overview